|
Post by seanismorris on May 16, 2019 17:24:02 GMT -5
Looks like they have two physical locations, one in Australia and another in New Zealand.
I’m not getting the sense that they are of significant size...
On the bright side, if Afrezza gets approved in AU it might automatically get approved in NZ...
I wouldn’t get too excited yet.
All these international announcements have been PR to date. Mike might just be feeling the heat, so he pops another of these out...
|
|
|
Post by mannmade on May 16, 2019 17:28:33 GMT -5
As I mentioned earlier 5% is still 60K scripts a year plus the refills for each script. That's quite a bit more than we are selling in the States currently almost twice as much. It will help on many fronts if we get 5% here and 5% there...
|
|
|
Post by awesomo on May 16, 2019 17:41:49 GMT -5
As I mentioned earlier 5% is still 60K scripts a year plus the refills for each script. That's quite a bit more than we are selling in the States currently almost twice as much. It will help on many fronts if we get 5% here and 5% there... How do you figure we can get higher sales in Australia than in the U.S., where we already have approval, has a much larger addressable market size, and have already invested a lot of resources into marketing/education/insurance coverage?
|
|
|
Post by bradleysbest on May 16, 2019 17:57:01 GMT -5
Good point!
|
|
|
Post by awesomo on May 16, 2019 17:58:36 GMT -5
From ST (BigPharmaBull) emailing Castagna about the deal...
|
|
|
Post by barnstormer on May 16, 2019 17:59:27 GMT -5
Another deal with no up front money and a small player. They aren't publically traded so it's difficult to understand how well capitalized they are. They sell a laundry list of products supporting PWD. Like Cipla & BIOOM there is no skin in the game that makes working approval processes a priority. No skin in the games also means Afrezza is just another product in their line along with pumps ect. Mike has set the bar low with these partners. I hope he jumps in with both feet to make Afrezza a success there. His effort with Cipla was beyond disappointing, relying on a company with no skin in the game taking the cheap and un assured path toward approval in India. He finally got on a plane and flew there after the cheap and easy path without a study was rejected. This is the fourth run at global expansion. Yes this is #4. He had an opportunity in UAE and turned them down almost two years ago. I hope above hope that the global expansion takes off this year, but Mike's performance so far isn't commensurate with the raise he just got. Come on Mike. Prove me wrong please.
|
|
|
Post by sportsrancho on May 16, 2019 18:00:59 GMT -5
|
|
|
Post by mnkdfann on May 16, 2019 18:04:48 GMT -5
From ST (BigPharmaBull) emailing Castagna about the deal... Apparently this is the email he sent, that garnered the reply above.
|
|
|
Post by sportsrancho on May 16, 2019 18:09:32 GMT -5
From Brett..
@bigpharmabull Hmmm. He responded to my email and said approximately 18 months for Australia approval.
|
|
|
Post by agedhippie on May 16, 2019 18:09:43 GMT -5
AMSL has about 80 people and revenue of $16M per qtr. This sounds like another BIOMM although at least this one doesn't make insulin. Oh, and they are the Tandem pump distributor in Australia.
|
|
|
Post by mnkdfann on May 16, 2019 18:18:32 GMT -5
AMSL has about 80 people and revenue of $16M per qtr. This sounds like another BIOMM although at least this one doesn't make insulin. Oh, and they are the Tandem pump distributor in Australia. If a small company has an opportunity to secure exclusive regional rights to something for (apparently) next to nothing, well, why not? If and when Afrezza takes off in the U.S. and Australians are clamoring for access to it, AMSL will be golden. Until then, I'm not sure that AMSL will have wherewithal or desire to do much with the rights.
|
|
|
Post by sportsrancho on May 16, 2019 18:28:17 GMT -5
|
|
|
Post by awesomo on May 16, 2019 18:37:38 GMT -5
AMSL has about 80 people and revenue of $16M per qtr. This sounds like another BIOMM although at least this one doesn't make insulin. Oh, and they are the Tandem pump distributor in Australia. If a small company has an opportunity to secure exclusive regional rights to something for (apparently) next to nothing, well, why not? If and when Afrezza takes off in the U.S. and Australians are clamoring for access to it, AMSL will be golden. Until then, I'm not sure that AMSL will have wherewithal or desire to do much with the rights. It will be like Cipla, BIOMM, Tanner, etc. (everything other than UTHR); nice for the partners if it happens, but no real investment if it doesn't amount to anything.
|
|
|
Post by longliner on May 16, 2019 18:41:38 GMT -5
I like everything about it. I voted no on all but Kresa (due to his $6. Purchase) this goes a long way toward aligning management and shareholder interests.
|
|
|
Post by ktim on May 16, 2019 18:53:44 GMT -5
I like everything about it. I voted no on all but Kresa (due to his $6. Purchase) this goes a long way toward aligning management and shareholder interests. I don't see your point on how this Australia deal has anything to do with management vs shareholder interests. Perhaps you can elaborate.
|
|